No signs of progressive beta cell damage during 20 years of prospective follow-up of autoantibody-negative diabetes.
Ekholm, Ella LU ; Gottsäter, Anders LU ; Dahlin, Lars LU
and Sundkvist, Göran
(2012)
In Acta Diabetologica
49.
p.57-62
- Abstract
- Both type 1 and type 2 diabetes are considered to be associated with different degrees of progressive beta cell damage. However, few long-term studies have been made. Our aim was to study the clinical course of 20 years of diabetes disease, including diabetes progression, comorbidity, and mortality in a prospectively studied cohort of consecutively diagnosed diabetic patients. Among all 233 patients diagnosed with diabetes during 1985-1987 in Malmö, Sweden, 50 of 118 surviving patients were followed-up after 20 years. The age at diagnose was 42.3 ± 23.1 and 57.5 ± 13.6 years for antibody-positive and antibody-negative patients, respectively. HbA1c and plasma lipids were analyzed with regard to metabolic control. Islet antibody-negative... (More)
- Both type 1 and type 2 diabetes are considered to be associated with different degrees of progressive beta cell damage. However, few long-term studies have been made. Our aim was to study the clinical course of 20 years of diabetes disease, including diabetes progression, comorbidity, and mortality in a prospectively studied cohort of consecutively diagnosed diabetic patients. Among all 233 patients diagnosed with diabetes during 1985-1987 in Malmö, Sweden, 50 of 118 surviving patients were followed-up after 20 years. The age at diagnose was 42.3 ± 23.1 and 57.5 ± 13.6 years for antibody-positive and antibody-negative patients, respectively. HbA1c and plasma lipids were analyzed with regard to metabolic control. Islet antibody-negative patients at diagnosis had highly preserved C-peptide levels after 20 years in contrast to antibody-positive patients (antibody negative: C-peptide 0 years 0.78 ± 0.47 and 20 years 0.70 ± 0.46 (nmol/l), P = 0.51 and antibody positive: C-peptide 0 years 0.33 ± 0.35 and 20 years 0.10 ± 0.18; P < 0.001. Islet antibodies but not age, BMI, or C-peptide at diagnosis were predictors of C-peptide levels at 20 years when analyzed by logistic regression (P < 0.05). HbA1c did not differ between the groups after 20 years. The 20-year mortality was higher among antibody-negative patients, dependent on the higher age at diagnosis in this group (number of deaths: antibody positive: 18 of 56 vs. antibody negative: 109 of 188, P < 0.001). Of the deceased, 79% had died from diseases or complications that may be associated with diabetes. We found no progressive beta cell damage in autoantibody-negative diabetes at a 20-year follow-up of the clinical course of diabetes. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1883797
- author
- Ekholm, Ella
LU
; Gottsäter, Anders
LU
; Dahlin, Lars
LU
and Sundkvist, Göran
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Diabetologica
- volume
- 49
- pages
- 57 - 62
- publisher
- Springer
- external identifiers
-
- wos:000299505600009
- pmid:21416148
- scopus:84861698991
- pmid:21416148
- ISSN
- 1432-5233
- DOI
- 10.1007/s00592-011-0273-1
- language
- English
- LU publication?
- yes
- id
- 5bfdfa23-c113-4b0f-9229-da8ea0347c42 (old id 1883797)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21416148?dopt=Abstract
- date added to LUP
- 2016-04-01 14:09:19
- date last changed
- 2024-01-09 23:35:20
@article{5bfdfa23-c113-4b0f-9229-da8ea0347c42,
abstract = {{Both type 1 and type 2 diabetes are considered to be associated with different degrees of progressive beta cell damage. However, few long-term studies have been made. Our aim was to study the clinical course of 20 years of diabetes disease, including diabetes progression, comorbidity, and mortality in a prospectively studied cohort of consecutively diagnosed diabetic patients. Among all 233 patients diagnosed with diabetes during 1985-1987 in Malmö, Sweden, 50 of 118 surviving patients were followed-up after 20 years. The age at diagnose was 42.3 ± 23.1 and 57.5 ± 13.6 years for antibody-positive and antibody-negative patients, respectively. HbA1c and plasma lipids were analyzed with regard to metabolic control. Islet antibody-negative patients at diagnosis had highly preserved C-peptide levels after 20 years in contrast to antibody-positive patients (antibody negative: C-peptide 0 years 0.78 ± 0.47 and 20 years 0.70 ± 0.46 (nmol/l), P = 0.51 and antibody positive: C-peptide 0 years 0.33 ± 0.35 and 20 years 0.10 ± 0.18; P < 0.001. Islet antibodies but not age, BMI, or C-peptide at diagnosis were predictors of C-peptide levels at 20 years when analyzed by logistic regression (P < 0.05). HbA1c did not differ between the groups after 20 years. The 20-year mortality was higher among antibody-negative patients, dependent on the higher age at diagnosis in this group (number of deaths: antibody positive: 18 of 56 vs. antibody negative: 109 of 188, P < 0.001). Of the deceased, 79% had died from diseases or complications that may be associated with diabetes. We found no progressive beta cell damage in autoantibody-negative diabetes at a 20-year follow-up of the clinical course of diabetes.}},
author = {{Ekholm, Ella and Gottsäter, Anders and Dahlin, Lars and Sundkvist, Göran}},
issn = {{1432-5233}},
language = {{eng}},
pages = {{57--62}},
publisher = {{Springer}},
series = {{Acta Diabetologica}},
title = {{No signs of progressive beta cell damage during 20 years of prospective follow-up of autoantibody-negative diabetes.}},
url = {{https://lup.lub.lu.se/search/files/3817879/1894698.pdf}},
doi = {{10.1007/s00592-011-0273-1}},
volume = {{49}},
year = {{2012}},
}